1. Vaccine for Diabetes—Where Do We Stand?
- Author
-
Dinesh Kumar Chellappan, Richie R. Bhandare, Afzal B. Shaik, Krishna Prasad, Nurfatihah Azlyna Ahmad Suhaimi, Wei Sheng Yap, Arpita Das, Pradipta Banerjee, Nandini Ghosh, Tanner Guith, Amitava Das, Sarannya Balakrishnan, Mayuren Candasamy, Jayashree Mayuren, Kishneth Palaniveloo, Gaurav Gupta, Sachin Kumar Singh, and Kamal Dua
- Subjects
diabetes ,vaccines ,clinical trials ,insulin ,GLP ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Diabetes is an endocrinological disorder with a rapidly increasing number of patients globally. Over the last few years, the alarming status of diabetes has become a pivotal factor pertaining to morbidity and mortality among the youth as well as middle-aged people. Current developments in our understanding related to autoimmune responses leading to diabetes have developed a cause for concern in the prospective usage of immunomodulatory agents to prevent diabetes. The mechanism of action of vaccines varies greatly, such as removing autoreactive T cells and inhibiting the interactions between immune cells. Currently, most developed diabetes vaccines have been tested in animal models, while only a few human trials have been completed with positive outcomes. In this review, we investigate the undergoing clinical trial studies for the development of a prototype diabetes vaccine.
- Published
- 2022
- Full Text
- View/download PDF